Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...
Dexamethasone implants improve visual and anatomical outcomes better than brolucizumab in patients with both DME and hyperreflective intraretinal dots.
Various types of topical therapies are effective for the treatment of periorbital dyschromia, including caffeine, growth factors, and more.
Early treatment of the first MOGAD acute attack may prevent future relapses and reduce long-term humoral autoimmunity in patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback